|
Top Story
Biosimilars in the US: Five Key Commercial Considerations
The landmark approval by the FDA of Novartis’ Zarxio means biosimilars have finally arrived on U.S. shores and companies entering this blossoming market should now be turning even greater attention to commercialization, says Rohit Sood. Here, he outlines five critical factors for companies entering the biosimilars market ...Read more
 Learn more
about how to leverage Data and Analytics to enhance Copay Program Performance with this White Paper and Case Study:
Strategy
Partnering in a Volume-to-Value Transformational Environment
In the shift from volume to value as the underlying driver in health care, pharma has only scratched the surface of possibility for new and non-traditional arrangements with a broader variety of partners with healthcare interests, writes Pharm Exec Editorial Advisory Board member Cliff Kalb ...Read more
Regulatory
Pharma Disclosures Draw Securities and Exchange Commission Scrutiny
The Securities and Exchange Commission (SEC) is focusing more on the accuracy and timeliness of biopharma company financial filings, particularly those related to regulatory actions involving FDA, writes Jill Wechsler ...Read more
Leadership
Deadline for Nomination: Pharm Exec’s 2015 Emerging Pharma Leaders
Pharm Exec is looking for the fresh faces of pharma leadership, and we'd like your input! Tell us who you think should be included as one of Pharmaceutical Executive's 2015 Emerging Pharma Leaders. Read more for details of how to nominate a colleague — or yourself. The deadline for this year’s entries is April 15
...Read more
Marketing
Patients, Physicians, and Payers… How Can Pharma Do It All?
The word ‘centric’ by definition means one, as in focused on a single entity. Yet, in today’s life sciences industry, companies are customer-centric and patient-centric and physician-centric – all combined. It's counterintuitive, if not overwhelming, writes Lisa Barbadora ...Read more
|
